RLMD · NASDAQ
Relmada Therapeutics (RLMD) Stock Price & Fundamentals
Relmada Therapeutics (RLMD) closed at $180.81 on Oct 9, 2026, down 0.30% from the previous close of $181.35.
Share price, past year
1Y −4.24%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $180.81 |
| Sep 30, 2026 | $179.59 |
| Aug 31, 2026 | $175.19 |
| Jul 31, 2026 | $175.17 |
| Jun 30, 2026 | $181.39 |
| May 29, 2026 | $181.32 |
| Apr 30, 2026 | $184.50 |
| Mar 31, 2026 | $188.64 |
| Feb 27, 2026 | $195.78 |
| Jan 30, 2026 | $190.40 |
| Dec 31, 2025 | $189.90 |
| Nov 28, 2025 | $188.13 |
| Oct 31, 2025 | $189.15 |
Key statistics
- Market cap
- $19.29B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$61.93M
- Shares outstanding
- 106.7M
- Dividend yield
- —
- 52-week range
- $171.56 – $197.89
Relmada Therapeutics's market cap is $19.29B, based on a share price of $180.81 and 106.7M shares outstanding as of Jun 30, 2026.
Financials
Relmada Therapeutics reported revenue of $5.13K for fiscal 2013, down 35.41% from fiscal 2012.
Relmada Therapeutics reported a net loss of $57.39M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2013ended Aug 31, 2013 | $5.13K | −35.4% | — | — | — | −$2.24M |
| FY2012ended Aug 31, 2012 | $7.94K | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2013ended Nov 30, 2013 | $1.85K | — | — |
| Q3 FY2013ended May 31, 2013 | $634.00 | — | — |
| Q2 FY2013ended Feb 28, 2013 | $2.35K | — | — |
| Q1 FY2013ended Nov 30, 2012 | $2.15K | — | — |
| Q3 FY2012ended May 31, 2012 | $400.00 | — | — |
| Q2 FY2012ended Feb 29, 2012 | $6.03K | — | — |
Company profile
- Name
- Relmada Therapeutics, Inc.
- Ticker
- RLMD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2222 Ponce De Leon Blvd. 3rd Floor, Coral Gables, FL 33134
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001553643
Recent SEC filings
- Sep 8, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 28, 2026
- May 28, 2026
- May 12, 2026
- May 12, 2026
- Mar 20, 2026
Frequently asked questions
What is Relmada Therapeutics's stock price?
Relmada Therapeutics (RLMD) closed at $180.81 on Oct 9, 2026, down 0.30% from the previous close of $181.35.
What is Relmada Therapeutics's market cap?
Relmada Therapeutics's market cap is $19.29B, based on a share price of $180.81 and 106.7M shares outstanding as of Jun 30, 2026.
How much revenue does Relmada Therapeutics make?
Relmada Therapeutics reported revenue of $5.13K for fiscal 2013, down 35.41% from fiscal 2012.
Does Relmada Therapeutics pay a dividend?
Relmada Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Relmada Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures